Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?
© Springer International Publishing Switzerland 2015Maciej Banach (ed.)Combination Therapy In Dyslipidemia10.1007/978-3-319-20433-8_16 16. Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance? Joanna Gozdzikiewicz-Lapinska1 and…